Aureon extends collaboration with Pfizer in prostate cancer treatment

The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome. The collaboration is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT).

Aureon technology is also being used to develop Prostate Px+, a prognostic, biopsy-based test which can assist men who are newly diagnosed with prostate cancer and need more accurate information to guide medical management of the disease. Prostate Px+ will be released in 2008.

Vijay Aggarwal, CEO and president of Aureon Laboratories, said: “Aureon’s ability to integrate and quantify histological features and cell-type specific molecular biomarkers in intact paraffin-embedded tissue allows a better understanding of the biological context in terms of assessing therapeutic response.”